Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. The primary objective of this study is to improve the tolerability and safety of elranatamab in patients with relapsed and/or refractory multiple myeloma by evaluating an outpatient and intermittent dosing strategy.

Trial Details

NCT ID
NCT06421675
Phase
PHASE2
Sponsor
Ontario Clinical Oncology Group (OCOG)
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Elranatamab injection
Locations (sample)
  • Vancouver, British Columbia, Canada|49.24966,-123.11934
  • Hamilton, Ontario, Canada|43.25011,-79.84963
  • Kingston, Ontario, Canada|44.22976,-76.48098
  • London, Ontario, Canada|42.98339,-81.23304
  • London, Ontario, Canada|42.98339,-81.23304

Key Eligibility Criteria

  • Relapsed and/or refractory MM defined as:
  • Documented evidence of progressive disease (PD) after achieving at least minimal response (MR) for ≥ 1 cycle during a previous MM treatment (i.e., …
  • Disease progression during or within 60 days from the end of the most recent MM treatment (i.e., refractory MM).
  • Measurable disease based on IMWG criteria, defined as at least one of the following, documented within 28 days before enrollment:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →